Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,715.00+1.30%ETH$2,288.66+1.82%GOLD$3,940.20-0.74%OIL$96.76+0.31%
Smart Investors Daily
SID Premium
GU

NASDAQ · GUTS

Fractyl Health, Inc. Common Stock

Healthcare · Biotechnology

$0.94

Down-$0.04 (-4.71%)

Updated Nov 3, 2026, 10:45 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
166.41M
P/E ratio
-1.22
Dividend yield
0.00%
52-week range
$0.42 – $6.99
Volume
242.06K
Avg. volume
4.08M

Price performance · GUTS

GUTS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

GUTS closed at $0.94 after 21 trading sessions, down 79.33% for the selected period.

Last close
$0.94
Period change
-79.33%
Period low
$0.88
Period high
$4.57
Daily close
View OHLC price history
GUTS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$0.9983$0.999$0.9163$0.9426242.06K
Oct 30, 2026$0.96$0.9798$0.90$0.9765387.01K
Oct 29, 2026$0.8932$1.02$0.8591$0.9915710.86K
Oct 28, 2026$0.8908$0.9131$0.8207$0.89582.04K
Oct 27, 2026$1.06$1.06$0.851$0.881.22M
Oct 26, 2026$1.08$1.12$1.02$1.07363.05K
Oct 23, 2026$1.15$1.16$1.06$1.08437.9K
Oct 22, 2026$1.23$1.25$1.12$1.13521.67K
Oct 21, 2026$1.36$1.37$1.11$1.151.01M
Oct 20, 2026$1.39$1.48$1.33$1.33477.96K
Oct 19, 2026$1.4399$1.52$1.37$1.381.15M
Oct 16, 2026$2.14$2.30$1.53$1.5515.1M
Oct 15, 2026$4.03$4.2095$3.92$4.1699.61K
Oct 14, 2026$4.05$4.21$3.78$4.08197.27K
Oct 13, 2026$4.46$4.50$4.00$4.025226.21K
Oct 12, 2026$4.41$4.5799$4.3463$4.41134.62K
Oct 9, 2026$4.21$4.55$4.20$4.42198.3K
Oct 8, 2026$4.50$4.5299$4.1401$4.23300.54K
Oct 7, 2026$4.53$4.73$4.431$4.52104.5K
Oct 6, 2026$4.56$4.75$4.40$4.57156.72K
Oct 5, 2026$4.80$4.8145$4.33$4.56291.22K

Latest GUTS news

The latest Smart Investors Daily articles mentioning GUTS.

Stock researchCompany · Overview

GUTS research

Overview

Company profile and research snapshot.

Company profile

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GUTS recent ratings
DateFirmRatingTarget
Oct 20, 2026Canaccord GenuityBuy—
Oct 19, 2026Morgan StanleyEqual-Weight—
Jul 1, 2026Craig-HallumBuy—
Jun 4, 2026HC Wainwright & Co.Buy—
Apr 24, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Fractyl Health (GUTS) Stock Sees Fair Value Cut After Mixed Revita Analyst Reactions

The average fair value estimate for Fractyl Health shifted from about US$60.40 to roughly US$47.83, echoing the sharp reset in Street price targets from US$96 to US$39 and from US$48 to US$5. Analysts are weighing the six month Revita pivotal data against concerns about execution risk, real world uptake and how much of the weight regain benefit is already reflected in the stock. Read on to see how this evolving narrative could shape your view on Fractyl Health over the coming...

Yahoo · Oct 22, 2026

Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance

Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program Cash runway extended into Q2 2027; quarterly operating cash

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By